D. Harvey

发表

Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.

Jonas Boström, P. Bach, M. O'Sullivan, 2013, European journal of medicinal chemistry.

Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma.

J. McDonald, Beatriz Ospina, J. Murtie, 2020, ACS medicinal chemistry letters.

Tandem reactions of anions: A short and efficient route to ±anatoxin-a

J. M. Underwood, N. Camp, P. Parsons, 1996 .

A general approach to the galanthamine ring system

P. Parsons, M. D. Charles, D. Harvey, 2001 .

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies

T. Riera, Katherine Cosmopoulos, K. Duncan, 2021, ACS medicinal chemistry letters.

Drug Discovery and Chemical Biology of Cancer Epigenetics.

R. Copeland, S. Ribich, D. Harvey, 2017, Cell chemical biology.

Inhibitors of Epigenetic Regulation in Cancer

M. Foley, D. Harvey, 2017 .

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Jodi Gureasko, W. Janzen, T. Riera, 2018, PloS one.

Identification of a peptide inhibitor for the histone methyltransferase WHSC1

K. Swinger, M. Morrison, W. Janzen, 2018, PloS one.

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.

L. Arik, E. Laird, V. Viswanadhan, 2007, Journal of medicinal chemistry.

5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor.

E. Laird, D. Clarke, Jonas Boström, 2013, Future medicinal chemistry.

Drug Discovery and Chemical Biology of Cancer Epigenetics.

R. Copeland, S. Ribich, D. Harvey, 2017, Cell chemical biology.